Shares of Northwest Biotherapeutics Inc. (PINK: NWBO), a development-stage biotechnology company engaged in the discovery, development and commercialization of immunotherapy products that generate and enhance immune system responses to treat cancers, are rallying in trading today.
At last check, NWBO shares were trading 20.25% higher at $0.380 on above average volume of 1.26 million. The stock has gained 34.29% in the last three trading sessions.
Earlier this week, NWBO announced that Fraunhofer IZI, the companyâ€™s partner in Germany, has received the official approval and certification from the regional and national regulatory agencies in Germany for the manufacture of NWBOâ€™s DCVaxÂ®-L immune therapy for human patients with Glioblastoma multiforme brain cancer.
Linda Powers, CEO of Northwest Biotherapuetics, said that the German regulatory process for manufacturing certification is extremely rigorous and detailed, with far more extensive requirements than some other European countries and it is a testament to the expertise and professionalism of NWBOâ€™s partners that DCVaxÂ®-L has now received the manufacturing certification.